In a patient receiving lithium therapy (300–900 mg daily), how does lithium increase the risk of nephrolithiasis and what preventive measures are recommended?

Lithium and Kidney Stones

Lithium therapy increases the risk of nephrolithiasis primarily through hypercalcemia secondary to lithium-induced hyperparathyroidism, which is associated with higher risk of kidney stone formation and CKD progression 1.

Mechanism of Lithium-Associated Nephrolithiasis

Lithium causes kidney stones through several interconnected pathways:

• Hyperparathyroidism-mediated hypercalcemia: Lithium disrupts parathyroid gland calcium sensing, leading to elevated parathyroid hormone (PTH) levels and subsequent hypercalcemia. This hypercalcemia directly increases urinary calcium excretion and stone formation risk 1.

• Nephrogenic diabetes insipidus (NDI): Lithium enters collecting duct cells via epithelial sodium channels and downregulates aquaporin-2, impairing urinary concentrating ability. The resulting polyuria and chronic dehydration increase urinary supersaturation of stone-forming salts 2.

• Chronic tubulointerstitial injury: Long-term lithium accumulation causes mitochondrial dysfunction and oxidative stress, leading to interstitial fibrosis that can alter urinary composition and promote stone formation 1.

The FDA label explicitly warns that chronic lithium therapy is associated with morphologic changes including glomerular and interstitial fibrosis 3, creating an environment conducive to stone formation.

Risk Factors for Stone Formation

Key risk factors that amplify nephrolithiasis risk in lithium-treated patients include:

• Episodes of lithium intoxication or overdose
• Longer treatment duration (>10 years carries higher risk)
• Dehydration states
• Concurrent medications that reduce renal lithium clearance (NSAIDs, ACE inhibitors, thiazide diuretics)
• Pre-existing kidney disease 1, 2

Preventive Measures

Primary Prevention Strategy

Increase fluid intake to achieve at least 2 liters of urine output daily 4. This is the cornerstone intervention supported by ACP guidelines and applies universally to lithium-treated patients.

• Distribute fluid intake throughout the day, not concentrated in one period
• Monitor for adequate hydration given lithium's propensity to cause NDI
• Patients with established NDI may require even higher fluid intake to compensate for concentrating defects

Monitoring Protocol

Implement systematic surveillance every 3 months (or every 8-10 weeks in elderly patients):

• Serum lithium levels (12-hour trough)
• Serum creatinine and eGFR
• Serum calcium and PTH levels to detect hyperparathyroidism early 1
• Urinalysis
• Consider 24-hour urine volume assessment 3

Pharmacologic Prevention

If stones develop despite adequate hydration, initiate pharmacologic monotherapy with thiazide diuretic, citrate, or allopurinol 4. However, this creates a clinical dilemma:

Critical caveat: The FDA label contraindicates lithium use with diuretics due to increased lithium toxicity risk 3. If thiazides are chosen for stone prevention, this requires:

• Extremely close monitoring with weekly lithium levels initially
• Likely lithium dose reduction (often 50% or more)
• Consider nephrology co-management
• Alternative: Citrate therapy (potassium citrate) is safer as it doesn't affect lithium levels and addresses hypocitraturia

Interestingly, one experimental study suggests lithium citrate formulation may actually increase urinary citrate and reduce stone formation 5, though this is not standard clinical practice.

Management of Hyperparathyroidism

When hypercalcemia is detected:

• Refer to endocrinology for parathyroid evaluation
• Consider parathyroidectomy if indicated, as this addresses the root cause of calcium stone formation 1
• This intervention can prevent both stone recurrence and CKD progression

When to Involve Nephrology

Mandatory nephrology consultation when:

• eGFR falls below 30 mL/min/1.73m² 6
• Recurrent stone episodes despite preventive measures
• Acute kidney injury develops
• Progressive decline in kidney function

Do not initiate lithium in elderly patients with eGFR <45 mL/min/1.73m² 6.

Clinical Decision Algorithm

1. All lithium patients: Increase fluid intake to ≥2L urine output daily
2. Monitor quarterly: Lithium level, creatinine, calcium, PTH
3. If hypercalcemia detected: Endocrine referral for hyperparathyroidism management
4. If stones develop despite hydration: Add potassium citrate (safer than thiazides with lithium)
5. If eGFR <30: Nephrology referral and reconsider lithium continuation
6. Avoid: Dehydration, NSAIDs, ACE inhibitors when possible

The decision to continue lithium when stones develop requires weighing psychiatric stability and suicide risk reduction against progressive renal injury—this must be individualized with psychiatry and nephrology input 2, 7.